By Michael Gwarisa Doctors Without Borders (MSF) has secured a limited supply of long-acting injectable cabotegravir (CAB-LA), a groundbreaking HIV prevention medication, following months of negotiations with Viiv, its sole manufacturer. The initial rollout is set to begin later this year in Zimbabwe, Mozambique, Malawi, and Eswatini. To prepare for this rollout, MSF conducted a four-day training workshop for clinicians, nurses, and future implementers. The training aimed to build capacity among healthcare workers to effectively administer CAB-LA and integrate it into HIV prevention efforts. Dr. Gerald Hangaika, from MSF’s Mbare…
Read MoreTag: CAB-LA
CAB-LA Enjoys High Continuity Rates Among PrEP Users In Zimbabwe
By Michael Gwarisa The recently introduced long-acting cabotegravir (CAB-LA) for HIV prevention has seen more users returning to get the second dose post their first jab, with data showing that the injectable drug has recorded a continuity rate over 90% since roll out in April, 2024. Currently, the Injectable PrEP is being administered in PrEP study sites in Harare, Mature and Bulawayo and is targeting mainly groups at high risk of HIV, namely Female Sex Workers (FSW), Adolescent Girls and Young Women (AGYW) and Men who have Sex with other…
Read MoreZim readies incorporation of Cabotegravir into local PrEP guidelines
FOLLOWING the approval for use of Cabotegravir (CAB-LA) in Zimbabwe by the Medicines Control Authority of Zimbabwe (MCAZ) last year, the country is expected to have incorporated the World Health Organization (WHO) guidelines of this long-acting HIV preventive method into its own HIV pre-exposure prophylaxis in June. By Kudakwashe Pembere That the WHO guidelines would be incorporated into Zimbabwe’s was revealed by renowned HIV Prevention expert Dr Nyaradzo Mgodi last week in a media science café organized by the Health Communicators Forum (HCF). Zimbabwe is the first African country to…
Read More